Company intelligence / Profile preview

Evolvere BioSciences

Oxford, England, United Kingdomevolvere.in ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

Evolvere BioSciences has demonstrated initial proof-of-concept for its AI-driven approach to developing next-generation antibiotics that outpace bacterial evolution. The company is currently in the lead optimization phase, aiming to create "future-proof" biologic therapeutics that precisely target pathogenic bacteria while sparing beneficial microbes and human cells. No clinical results are available yet as programs are preclinical.

Therapeutic areas: Infectious Diseases
Modalities: BiologicProtein
Industry: Biotech

Partnerships

Y Combinator S24 batch participant/investor partnershipUniversity of Oxford/BioEscalator support/collaboration for early-stage development and lab space access

Beyond the preview

Go deeper on Evolvere BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evolvere BioSciences.

Explore the full profile